Research programme: anti-botulinum neurotoxin monoclonal antibodies - Morphotek

Drug Profile

Research programme: anti-botulinum neurotoxin monoclonal antibodies - Morphotek

Alternative Names: Botulinum neurotoxin therapeutics - Morphotek

Latest Information Update: 13 Apr 2011

Price : $50

At a glance

  • Originator Morphotek
  • Class Monoclonal antibodies
  • Mechanism of Action Botulinum toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Research Botulism

Most Recent Events

  • 26 Sep 2008 Morphotek Inc enter into an agreement to access Pivotal BioScience's LEC platform technology for the development of therapeutic monoclonal antibodies
  • 20 Sep 2007 Early research in Botulism in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top